PREVAIL IV: Double-Blind, Randomized, Two-Phase, Placebo-Controlled, Phase II Trial of GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen

Trial Profile

PREVAIL IV: Double-Blind, Randomized, Two-Phase, Placebo-Controlled, Phase II Trial of GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs GS 5734 (Primary)
  • Indications Ebola virus infections
  • Focus Therapeutic Use
  • Acronyms PREVAIL IV
  • Most Recent Events

    • 24 Jun 2017 Planned End Date changed from 1 Jun 2018 to 26 Jan 2018.
    • 24 Jun 2017 Planned primary completion date changed from 1 Jun 2018 to 29 Dec 2019.
    • 26 Apr 2017 Planned End Date changed from 1 Nov 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top